Smoker

Most Smoking Employees Gain Over Three Weeks of Paid Time Off Through Smoke Breaks According to New Study

Retrieved on: 
Thursday, April 4, 2024
Research, Telecommunications, Smoker, Smoking, Environment, Tobacco

The study underscores the importance of promoting productive breaks among employees that do not significantly disrupt the workday.

Key Points: 
  • The study underscores the importance of promoting productive breaks among employees that do not significantly disrupt the workday.
  • The study also showed that smoking at work exacerbates the difficulty of quitting, with over 60% of respondents citing workplace smoking as a barrier.
  • “The study revealed high smoking rates in industries such as retail, catering and leisure, IT and telecommunications, and healthcare.
  • To learn more about the global transformation of inspiring smokers to conscious enjoyment and explore smoke-free alternatives available across the US, visit www.nicokick.com .

New to The Street and Hempacco Co., Inc. Sign Three Month Media Contract

Retrieved on: 
Thursday, March 28, 2024
Fox Business, Growth, Entrepreneurship, Digital, Social media, Smoker, Tobacco, Interview, Smoke, CBD, Cannabis, IP, Hemp, Dennis Eichhorn

NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- New to The Street and Hempacco Co., Inc. (NASDAQ: HPCO) ($HPCO) ("Hempacco") signed a three-month media contract.

Key Points: 
  • NEW YORK, March 28, 2024 (GLOBE NEWSWIRE) -- New to The Street and Hempacco Co., Inc. (NASDAQ: HPCO) ($HPCO) ("Hempacco") signed a three-month media contract.
  • The New to The Street's social media team will share media content, creating a platform to increase awareness about HPCO.
  • New to The Street is a perfect media platform to inform many about HPCO's hemp CBD product offerings and collaborations.
  • I look forward to continuing with the professional media experts at New to The Street."

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, April 9, 2024
Science, Biotechnology, Research, Pharmaceutical, Health, Tobacco, Clinical Trials, Retail, Disease, Cardiovascular Research, Society, IND, Psychology, Therapy, Senior counsel, Population health, School, Dean (education), Partnership, Nicotine, Policy, Smoker, Behavior, NIH, Brown University, Trial of the century, University, SAB, Pharmacology, Homelessness, San Francisco General Hospital, UCSF, Public, Cancer, MD, Publication, Heated tobacco product, Hospital, Juul, FDA, Alpert Medical School, Pregnancy, Chair, Public health, University of Kansas, Cardiology, CTA, Mortality, Louisiana State University, Doctor of Philosophy, MHRA, Smoking, Toxicology, Division, Brown, Social science, Pharmaceutical industry

“We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.

Key Points: 
  • “We believe our proprietary drug-device combination platform has the potential to be a first-in-class and best-in-class treatment for smoking cessation.
  • Last fall, QN-01 demonstrated a superior pharmacokinetic profile compared to existing nicotine replacement therapies in our first-in-human Phase 1 clinical trial.
  • We plan to submit our IND and CTA to the regulatory bodies and look forward to commencing our Phase 1/2 clinical study this year.
  • He also served a three-year term on the Board of the Society for Research on Nicotine and Tobacco.

Innovation Meets Regulation: International Webinar Explored Effective Anti-Smoking Strategies

Retrieved on: 
Tuesday, April 9, 2024
Retail, Other Communications, Public Policy, Technology, Marketing, Consulting, Advertising, Communications, Professional Services, Government, Tobacco, Science, Other Science, Internet, Research, Failure, Tax, Herbal cigarette, Innovation, European Parliament, Risk, Public, Smoker, Policy, Smoke, MEP, Death, Smoking, European, Multimedia, Carcinogen

We Are Innovation hosted the webinar “ Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index .” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index .

Key Points: 
  • We Are Innovation hosted the webinar “ Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index .” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index .
  • The webinar, featuring Members of the European Parliament, regulatory experts, economists, and innovation experts, shed light on the regulatory frameworks regarding anti-smoking policies from the most prominent global authorities in the field.
  • View the full release here: https://www.businesswire.com/news/home/20240408705665/en/
    Federico N. Fernández stated, “At We Are Innovation, we work on issues that require innovative approaches and solutions.
  • By embracing a forward-thinking approach, we can effectively address the problem of smoking,” summed up Tetiana Rak.

Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting

Retrieved on: 
Wednesday, March 20, 2024
Research, Harvard Medical School, Massachusetts General Hospital, Nicotine, Smoker, NIH, Society, Smoking, Safety, Bangladesh Technical Education Board, Annual general meeting, Tobacco

March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.

Key Points: 
  • March 21, 2024, 11:30 AM GMT: Achieve’s Director of Clinical Operations, Roxann Becco, will present patient-reported outcomes from the Phase 3 ORCA-2 and ORCA-3 clinical trials.
  • Data collected include trial participants’ experiences, such as cravings and withdrawal symptoms, personal impact on overall health, and opinions on future use.
  • ORCA-V1 evaluated the effectiveness and safety of cytisinicline in users of nicotine e-cigarettes who wanted to quit vaping.
  • The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH.

Global Transdermal Medical Patch Market Analysis and Forecast to 2029: Growing Number of Smokers, Rising use for Insulin Delivery and Upswing in Hormonal Deficiencies Drives Demand - ResearchAndMarkets.com

Retrieved on: 
Monday, April 1, 2024
Medical Supplies, Retail, Health, Tobacco, General Health, Pharmaceutical, Biotechnology, Hypersensitivity, Plasma, Obesity, Growth, Prevalence, Rheumatoid arthritis, Application, Incidence, Diabetes, Patient, Pharmacy, Conditional sentence, Chronic pain, Stroke, Hospital, Smoker, Cancer, Nature, Migraine, Distribution, Arthritis, Nausea, Diabetic neuropathy, Smoking, Skin, Pain management, Pain, Allergy, Market, Vomiting, Osteoarthritis, Ageing, Pharmaceutical industry

The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Transdermal Medical Patch Market: Analysis By Type, By Application, By Distribution Channel, By Region Size & Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The global transdermal medical patch market was valued at US$7.88 billion in 2023 and is expected to reach US$10.33 billion by 2029.
  • The global transdermal medical patch market is highly competitive in nature, characterized by fierce competition among industry leaders vying to expand their market presence.
  • The key players in the global transdermal medical patch market are:

Rolaids® Bolsters Presence in Convenience Stores Through Strategic Partnership with Lil’ Drug Store Products

Retrieved on: 
Wednesday, March 27, 2024
Women, Supermarket, Convenience Store, Other Health, General Health, Pharmaceutical, Consumer, Health, Cosmetics, Retail, LDSP, Partnership, Smoker, Acquisition, Heartburn, Marketing, P&G, Procter & Gamble, Advertising

Lil’ Drug Store Products (LDSP) announces a strategic partnership with Procter & Gamble (P&G) for the preferred distribution of Rolaids® – the trusted heartburn relief brand – to convenience and travel retailers nationwide.

Key Points: 
  • Lil’ Drug Store Products (LDSP) announces a strategic partnership with Procter & Gamble (P&G) for the preferred distribution of Rolaids® – the trusted heartburn relief brand – to convenience and travel retailers nationwide.
  • Following P&G’s acquisition of Rolaids, LDSP has emerged as the primary distributor, leading the reintroduction of its diverse product range into key retail channels.
  • This collaboration solidifies LDSP's pivotal role as the convenience distributor of choice for Rolaids, further reinforcing its position as a category leader in the industries it serves.
  • With approximately 45% of heartburn sufferers also identifying as smokers, this underscores the vital role of convenience stores in reaching many individuals experiencing heartburn.

BRITISH AMERICAN TOBACCO 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against British American Tobacco p.l.c - BTI

Retrieved on: 
Friday, March 22, 2024
Legal, Professional Services, Reynolds American, KSF, ADR, District court, Tobacco, History, Smoker, News, BTI, British American Tobacco, Special warfare combatant-craft crewmen, American Tobacco Company, Court, The Wall Street Journal

This action is pending in the United States District Court for the Eastern District of New York.

Key Points: 
  • This action is pending in the United States District Court for the Eastern District of New York.
  • BA Tobacco and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
  • The case is David v. British American Tobacco p.l.c., et al., No.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

Philip Morris International Launches New IQOS ILUMA i in Japan to Accelerate the Achievement of a Smoke-Free Future

Retrieved on: 
Wednesday, March 13, 2024
Technology, Tobacco, Retail, Consumer Electronics, Smoke, Philip Morris International, Taste, Olczak, Science, Risk, PMI, Research, Smoker, Sale, Life, ZYN, System, Nicotine, IQOS, Toxicology, Q3, Aluminium, Government, Food

1 tobacco heating system.1 The launch also marks the 10-Year anniversary of IQOS, originally launching in Nagoya, Japan in 2014.

Key Points: 
  • 1 tobacco heating system.1 The launch also marks the 10-Year anniversary of IQOS, originally launching in Nagoya, Japan in 2014.
  • Within 10 years, IQOS net revenues have surpassed those for Marlboro, making it the number one international nicotine brand and accelerated the decline of cigarettes in many countries.
  • In Japan, for example, nearly one-third of adult smokers are using IQOS2 and cigarette sales have declined much more rapidly since heated tobacco was launched.
  • It is important that others—like government authorities and regulators—embrace the opportunity offered by innovation and science to benefit the world.”
    The IQOS ILUMA i series offers three devices in Japan: IQOS ILUMA i PRIME, IQOS ILUMA i and IQOS ILUMA i ONE.

White House Misses Another Deadline to Finalize Rule Prohibiting Menthol Cigarettes - Delays Cost Lives, Especially Black Lives

Retrieved on: 
Monday, April 1, 2024
Research, NAACP, Health, Tobacco industry, Conference, Organization, The Washington Post, Health equity, Public, African Americans, Smoker, Policy, Delays, Mayor, Smoking, Congressional Black Caucus, Multimedia, Administration, FDA, Tobacco

WASHINGTON, April 1, 2024 /PRNewswire/ -- It is profoundly disappointing and harmful to public health that the Biden Administration has missed yet another deadline to issue a final FDA rule eliminating menthol cigarettes. The Administration delayed issuing the final rule in December and now has missed the new deadline it set to issue the rule by March 2024.

Key Points: 
  • Make no mistake: Delays cost lives, especially Black lives.
  • Delays allow the tobacco industry to continue its predatory targeting of Black and other communities with menthol cigarettes, resulting in 45,000 Black lives lost to smoking-related diseases every year.
  • If Black lives truly matter, it's time to get rid of menthol cigarettes, the only flavored cigarettes still on the market.
  • Research shows that eliminating menthol cigarettes will save up to 654,000 lives within 40 years, including 255,000 Black lives.